AI Article Synopsis
- Zebrafish are emerging as a valuable model for studying reward and addiction, showing relevant behaviors in response to drugs.
- They demonstrate sensitivity to various substances, tolerance development, and have been used to model withdrawal effects.
- The review explores recent findings, challenges in research, and suggests future directions for drug abuse studies using zebrafish.
Article Abstract
Mounting evidence implicates the zebrafish (Danio rerio) as a promising model species for reward and addiction research. Modeling drug abuse-related behavior in both adult and larval zebrafish produced a wealth of clinically translatable data, also demonstrating their sensitivity to various drugs of abuse and the ability to develop tolerance. Several studies have also applied withdrawal paradigms to model the adverse effects of drug abuse in zebrafish. In this review, we summarize recent findings of a wide spectrum of zebrafish drug abuse-related behavioral and physiological phenotypes, discuss the existing challenges, and outline potential future directions of research in this field.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1515/RNS.2011.011 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Ayahuasca for the treatment of alcohol use disorder.
Int Rev Neurobiol
November 2024
Department of Health Sciences, Universidade Estadual de Santa Cruz, Ilhéus, BA, Brazil; Department of Psychiatry and Human Behavior, Center for Innovation and Discovery in Addictions, University of Mississippi Medical Center, Jackson, MS, United States.
For decades, psychedelics have been investigated for the treatment of psychiatric disorders. Specifically, evidence suggests that psychedelics may have therapeutic potential for the treatment of alcohol use disorder. Several studies with classic psychedelics, including LSD and psilocybin, show promising results, with psychedelics decreasing alcohol drinking and promoting abstinence in individuals with alcohol use disorder.
View Article and Find Full Text PDFAlternative Reinforcers Enhance the Effects of Opioid Antagonists, but Not Agonists, on Oxycodone Choice Self-Administration in Nonhuman Primates.
J Pharmacol Exp Ther
October 2024
Behavioral Neuroimaging Laboratory, McLean Hospital, Belmont, Massachusetts (F.B.d.M., S.J.K.) and Department of Psychiatry, Harvard Medical School, Boston, Massachusetts (F.B.d.M., S.J.K.)
Clinical reports suggest that the most effective strategies for managing opioid use disorder comprise a comprehensive treatment program of both pharmacological and nonpharmacological approaches. However, the conditions under which these combinations are most effective are not well characterized. This study examined whether the presence of an alternative reinforcer could alter the efficacy of Food and Drug Administration-approved opioid antagonist or agonist medications, as well as the nonopioid flumazenil, in decreasing oxycodone choice self-administration in nonhuman primates.
View Article and Find Full Text PDFPsilocybin-assisted therapy and HIV-related shame.
Sci Rep
August 2024
Department of Psychiatry and Behavioral Sciences, University of California, San Francisco, Sandler Neurosciences Bldg., Rm 510, 675 Nelson Rising Lane, San Francisco, CA, 94143, USA.
As a proposed mediator between stigma-related stressors and negative mental health outcomes, HIV-related shame has been predictive of increased rates of substance use and difficulties adhering to antiretroviral treatment among people with HIV. These downstream manifestations have ultimately impeded progress toward national goals to End the HIV Epidemic, in part due to limited success of conventional psychotherapies in addressing HIV-related shame. In a pilot clinical trial (N = 12), receipt of psilocybin-assisted group therapy was associated with a large pre-post decrease in HIV-related shame as measured by the HIV and Abuse Related Shame Inventory, with a median (IQR) change of - 5.
View Article and Find Full Text PDFCo-stimulation of muscarinic M1 and M4 acetylcholine receptors prevents later cocaine reinforcement in male and female mice, but not place-conditioning.
Prog Neuropsychopharmacol Biol Psychiatry
August 2024
Laboratory of Neuropsychiatry, Psychiatric Centre Copenhagen, Mental Health Services in the Capital Region of Denmark and Copenhagen University Hospital - Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark; Department of Neuroscience, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. Electronic address:
Acute stimulation of M or M muscarinic cholinergic receptors reduces cocaine abuse-related effects in mice and rats. The combined activation of these receptor subtypes produces synergistic effects on some behavioural endpoints in mice. M and M + M receptor stimulation in a cocaine vs.
View Article and Find Full Text PDFEffects of cocaine, nicotine, and marijuana exposure in Drosophila Melanogaster development: A systematic review and meta-analysis.
Prog Neuropsychopharmacol Biol Psychiatry
August 2024
Institute of Biological Sciences and Health, Federal University of Alagoas (UFAL), Maceió, AL, Brazil. Electronic address:
Abuse-related drug usage is a public health issue. Drosophila melanogaster has been used as an animal model to study the biological effects of these psychoactive substances in preclinical studies. Our objective in this review is to evaluate the adverse effects produced by cocaine, nicotine, and marijuana during the development of D.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!